TNFRSF8 and anaplastic large cell lymphoma: With the exception of brentuximab vedotin for CD30‐expressing anaplastic large cell lymphoma (ALCL), other agents including FDA‐approved pralatrexate and histone deacetylase inhibitors have not demonstrated a survival benefit (Fiore et al, 2020).